Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
369.43+17.78 (+5.06%)
At close: 04:00PM EST
370.00 +0.57 (+0.15%)
After hours: 05:09PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close351.65
Open358.29
Bid369.29 x 800
Ask370.00 x 1200
Day's Range355.16 - 369.98
52 Week Range335.68 - 555.77
Volume1,236,694
Avg. Volume865,553
Market Cap57.742B
Beta (5Y Monthly)0.89
PE Ratio (TTM)60.47
EPS (TTM)6.11
Earnings DateFeb 09, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est437.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
23% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ILMN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Illumina, Inc.
    Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
Advertisement
Advertisement